Compare iShares Silver Trust (SLV) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Silver Trust vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares Silver Trust trades at $50.63 (market cap $29.73B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: iShares Silver Trust is far larger — about 6.1× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Silver Trust for 90 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SLV | TVTX | |
|---|---|---|
Market Cap | $29.73B | $4.88B |
Volume | 17,545,887 | 1,668,577 |
52-Week High | $105.57 | $67.52 |
52-Week Low | $42.40 | $26.79 |
Typical Hold Time | 90 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLV, the iShares Silver Trust ETF, is trading at $50.22, down 7.6% over 24 hours amid a bearish technical signal. The trust holds substantial assets of $13.41 billion with minimal liabilities, but financial metrics like P/E and revenue are unavailable. Recent news highlights pressure from rising Treasury yields and a stronger dollar, contributing to silver's sharp decline.
The outlook remains cautious due to macroeconomic headwinds and Fed policy uncertainty. While silver's industrial and monetary appeal offers long-term potential, near-term volatility and bearish technical indicators suggest limited upside. Risks include interest rate sensitivity and market sentiment shifts, requiring careful monitoring for entry points.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
